- Home
- Slides
- Home
- Tools and Resources
- Research Summaries for Consumers, Clinicians, and Policymakers
- Search for Research Summaries, Reviews, and Reports
- Research Available for Comment
- Submit a Suggestion for Research
- Submit Scientific Information Packets
- Comparative Effectiveness Research Grant and ARRA Awards
- News and Announcements
- What Is Comparative Effectiveness Research
- Who Is Involved in the Effective Health Care Program
- What Is the Effective Health Care Program
Slides
Slides: 1–9 of 9
Clinically Significant Outcomes of Interest (2 of 2)
Clinical Questions Addressed by the CER (1)
Presentation: Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients with Cystic Fibrosis
Keywords: intermediate outcomes | health outcomes | pulmonary function | body composition | bone mineralization | pulmonary exacerbation | mortality risk | health related quality of life | HRQoL | QoL | quality of life | cystic fibrosis | CF | rhGH | recombinant human growth hormone | human growth hormone | HGH
Outcomes of Interest in Studies of rhGH Treatment of Patients With CF
Presentation: Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients with Cystic Fibrosis
Keywords: intermediate outcomes | health outcomes | outcomes | pulmonary function | anthropometrics | bone mineralization | exercise tolerance | hospitalization rate | intravenous antibiotics | antibiotic use | health related quality of life | HRQoL | QoL | quality of life | bone consequences | mortality | cystic fibrosis | CF | rhGH | recombinant human growth hormone | human growth hormone | HGH
Intermediate End Points and Health Outcomes in rhGH-Treated Patients With CF (1)
Presentation: Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients with Cystic Fibrosis
Keywords: intermediate | outcome | end point | health outcome | mortality | health related quality of life | HRQoL | QoL | quality of life | cystic fibrosis | CF | rhGH | recombinant human growth hormone | human growth hormone | HGH
Intermediate End Points and Health Outcomes in rhGH-Treated Patients With CF (2)
Intermediate End Points and Health Outcomes in rhGH-Treated Patients With CF (3)
Presentation: Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients with Cystic Fibrosis
Keywords: regression | multivariate | univariate | anthropometrics | mortality | health related quality of life | HRQoL | QoL | quality of life | cystic fibrosis | CF | rhGH | recombinant human growth hormone | human growth hormone | HGH
Intermediate End Points and Health Outcomes in rhGH-Treated Patients With CF (4)
Presentation: Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients with Cystic Fibrosis
Keywords: CF | HGH | HRQoL | QoL | anthropometrics | cystic fibrosis | health related quality of life | human growth hormone | mortality | multivariate | pulmonary function | quality of life | recombinant human growth hormone | regression | rhGH | univariate
Summary of Benefits (2)
Presentation: Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients with Cystic Fibrosis
Keywords: BMC | bone mineral content | percent predicted FEV1 | fracture risk | mortality | health related quality of life | HRQoL | QoL | quality of life | cystic fibrosis | CF | rhGH | recombinant human growth hormone | human growth hormone | HGH
Summary of Evaluation and Treatment Monitoring
Your slide tray is being processed.